Browse drugs

… and consistently after 12 months. These findings suggests that anifrolumab could reduce organ damage accumulation, supporting the potentia…

… Due to therapeutic failure with rituximab, she was switched to anifrolumab. Twelve days after the first infusion, she developed a painful …

…luation of urine uracil as a potential biomarker of response to anifrolumab.…

…e experience of patients with moderate-to-severe SLE initiating anifrolumab treatment through routine clinical practice as part of two earl…

… vs 26.2%, p=0.1718; IS-experienced, 27.7% vs 16.2%, p=0.0038). Anifrolumab was well tolerated, regardless of reported IS history; safety w…

…mean current age of 45.3 years. Biologic therapies consisted of Belimumab in 47 patients (56.0%), Anifrolumab in 26 (31.0%), and Rituxima…

…ling is a central driver of systemic lupus erythematosus (SLE). Anifrolumab, an anti-IFNAR1 monoclonal antibody, improves outcomes in moder…

…en strongly linked to the underlying disease mechanisms of SSc. Anifrolumab, a Type I IFN receptor inhibitor, is currently approved for pat…

…fections, most notably sepsis and influenza, when compared with belimumab, and these differences became more evident with longer exposure…

…frolumab treatmentConclusions In this real-world Danish cohort, anifrolumab produced substantial and sustained reductions in disease activi…

… all patients. There were no adverse events associated with the anifrolumab treatment.Abstract PO:11:288 Table 1Baseline characteristics of…

…ation 10.9 years were included. The main reasons for initiating anifrolumab were cutaneous manifestations in 5 patients (41.7%), articular …